Karen Fagan, MD
Associate Professor of Internal Medicine and Pharmacology
Chief, Pulmonary and Critical Care Division
University of South Alabama
Mobile, Alabama
Courses
Journal Articles
- Future Perspectives for the Treatment of Pulmonary Arterial Hypertension
The task presented to the Future Perspectives working group at the 4th World Symposium on Pulmonary Hypertension meeting in Dana Point was daunting: to identify what can be expected in the near future in the treatment of this complex disease process.
- Guest Editor's Memo
Highlights of the Scientific Sessions at PHA's International Conference
- Guest Editor's Memo
- Guest Editor's Memo
From PHA's Scientific Sessions, a Time for Reflection on the Progress Toward a Cure
- National Heart Lung and Blood Institute Hopkins Specialized Center in Clinical Oriented Research (SCCOR): Molecular Determinants of Pulmonary Arterial Hypertension
Recently, the National Heart, Lung, and Blood Institute awarded 2 Specialized Centers of Clinically Oriented Research (SCCOR) program grants in pulmonary hypertension. The SCCOR program requires clinical and basic scientists with a broad range of skills to work together on a unified theme, with special emphasis on clinically relevant research.
- PH Roundtable
International Conference Scientific Sessions: Past, Present, and Future
- PH Roundtable: Perspectives on PHA’s 10th International PH Conference
- Potential Genetic Contributions to Nonidiopathic, Nonfamilial Pulmonary Hypertension
The recent Venice Classification of pulmonary hypertension1 includes diseases that are definitely or possibly genetic and associated with the development of pulmonary hypertension.
- Pulmonary Arterial Hypertension: Therapeutic Considerations
Editor-in-Chief Victor Tapson, MD, interviewed a select panel of experts in pulmonary hypertension to obtain their review and comments on the new evidence-based clinical practice guidelines of the American College of Chest Physicians.
- Pulmonary Hypertension Roundtable
Recapping Highlights from the 2006 PHA Scientific Sessions
Reviewing New Perspectives on Inflammation, Genetics, and Imaging
Redefining Exercise-Induced PH
Future Considerations in Translational Research
- Pulmonary Hypertension Roundtable
PHA Scientific Sessions Provide a Great Window Into Treatment Breakthroughs While Inspiring Physicians and Patients Alike
- Pulmonary Hypertension Roundtable Discussion
Are we using PAH-specific therapies in non-WHO group I patients, and if so, how and why are we using them?
- Scleroderma-Associated Pulmonary Hypertension: Who's at Risk and Why
Pulmonary hypertension complicates several of the connective tissue diseases (Table 1). Scleroderma is a progressive, multisystem disease manifested by connective tissue and vascular lesions in many organs, including lung, kidney, and skin.
Presentations
